| | Oncostatin M synergistically inhibits HCV RNA replication in combination with interferon-αEdited by Hans-Dieter Klenk Received 23 February 2009; received in revised form 17 March 2009; accepted 24 March 2009. published online 31 March 2009. Abstract Oncostatin M (OSM), a member of the interleukin-6 family, possesses various functions, including hepatocyte differentiation and suppression of melanoma cell growth. Here, we report anti-hepatitis C virus (HCV) activity of OSM as a new function of this cytokine. OSM possessed marked anti-HCV activity (50% effective concentration: 0.71 ng/ml) in an HCV RNA replication cell culture system. The most striking finding is that OSM exhibited synergistic inhibitory activity on interferon (IFN)-α even at a low concentration with weak anti-HCV activity, such as 25pg/ml. OSM is a candidate anti-HCV reagent and may improve the current IFN therapy for patients with chronic hepatitis C. Abbreviations: SVR, sustained virological response, CH C, chronic hepatitis C, EC50, 50% effective concentration, EMCV, encephalomyocarditis virus, gp130, glycoprotein 130, HCV, hepatitis C virus, PEG-IFN, pegylated-interferon, IL, interleukin, IRES, internal ribosomal entry site, LIF, leukemia-inhibitory factor, NS, non-structural, OSM, oncostatin M, RBV, ribavirin, RL, Renilla luciferase, RT-PCR, reverse transcription-polymerase chain reaction, STAT, signal transducer and activator of transcription Department of Tumor Virology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan  Corresponding author. Fax: +81 86 235 7392.
PII: S0014-5793(09)00243-9 doi:10.1016/j.febslet.2009.03.054 © 2009 Federation of European Biochemical Societies | |
|
|
ABSTRACT
